about
Clinical characteristics and outcome of immunoglobulin M-related disorders.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation?Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.The possible role of burden of therapy on the risk of myeloma extramedullary spread.DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases.Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.Monoclonal gammopathy of undetermined significance: a new proposal of workup.Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature.Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls.Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.
P50
Q33365613-6D17948B-8DB2-4F91-8D71-A08BC2B9FA9DQ33617237-67C1BE76-218C-4128-B7B9-7A16BF1A8C79Q33824350-167EEE15-1CE7-4BBE-B3B8-5C6A48FB4ABEQ36715896-04D08DFD-B040-4053-97B3-2D19EE31309EQ37066535-11B3BDF2-75DD-4AD1-9CB9-F90B8033E677Q37499211-E2355664-8D43-4B48-8DB6-5E665E8A1EFFQ38491642-105EDF67-9DD0-4DDC-BD4A-FCC69ABD17BFQ38878814-E36BFF3E-6FE9-4C46-91F6-2EB3877D82E4Q39264310-BF618AF4-A9BB-4202-BB23-C37311E73503Q40427962-51C1156B-BA1A-4E61-9B1A-BB4CA4E317B9Q41696221-94F9D3F6-553E-4350-8314-761375F44F5EQ42165336-C1595074-4DCD-4BE7-9716-8491E658CEE5Q42509459-E1630F38-2032-409C-AC7D-7073BD686BB1Q43143104-65AE7CAB-328B-490B-8056-3EF56506AC67Q43292974-F08339F8-4787-40F9-926C-0C3A7EE25E66Q43417443-C1781667-E874-4F85-B69B-C31A41913CBEQ43504840-2C9238D8-F536-402E-A711-2E14067E3A23Q43706086-34EC8DB1-AC9C-4E56-B259-889AB7E7FE31Q43898090-B5A79397-DFFD-4BF8-B4E4-E1128FBCC701Q44119338-636E69CC-2750-4E1E-8284-E3F23BE17A24Q44580273-8429DDF2-34CD-489E-92B4-0873A2343CFDQ44965024-E75ABEA9-5EE9-48D2-81AE-07C9806FB87BQ44991602-E88919E7-47C6-4BDE-A3BE-C1EDF63B14B6Q46046656-2E55D67E-6DA1-4F5B-A270-64AB409E1E82Q46238714-DF006B2A-56D6-44E9-A9FD-868871293D53Q46491760-7E24A1D1-9878-486A-997C-59C6D12325F3Q46693258-657841B3-8F29-41E2-A085-D48CE9A207D1Q46838866-E4684F9A-DD86-4B14-A750-54F7E3049560Q46904224-327D646C-549D-4355-8A3D-A2ABD5B01631Q47140051-59202CC9-C67E-46D8-AF74-E5EC986ACA92Q47144661-26A5DFA0-3E41-4315-9560-2747F42AD07BQ47229522-37D63676-EDBA-4B78-9D86-E2E9CC602536Q48975240-2F13ECFB-06E4-437B-B36C-FC58468AA91AQ51438121-5D73BCF0-F95B-4BC0-85B4-7CAD297F919AQ51483185-5A4DB235-BAE1-477F-A367-FC3F67626B34Q52969991-D17C622F-C2D6-43B8-8C3A-DF52045392A7Q53470786-DC03438F-2DAF-4D5D-9B49-E82E50049B30Q53506683-CD6604D1-662A-4BAB-9DC7-00E7541C3025Q53851430-B8C0B18E-8ED8-4250-9771-B8A3E917802CQ54339929-60D1D044-0CA8-4BB6-ACD9-AC607A468F75
P50
description
researcher
@en
name
M Varettoni
@en
M Varettoni
@nl
type
label
M Varettoni
@en
M Varettoni
@nl
prefLabel
M Varettoni
@en
M Varettoni
@nl
P106
P31
P496
0000-0001-7304-1629